Sp572
WHAT TO DO ABOUT EGJOO?
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
This session provides a deeper understanding of how and when to use our current state of the art tools for physiology testing. Audience members will appreciate the nuances of esophageal motility reading, when to order which pH test for reflux symptoms. This session will also focus on the currently identified esophageal motility disorders as per the Chicago Classification version 4.0. This will highlight potential therapeutic options for these disorders. Attendees will hear about non-achalasia motility disorders and focus on current studies that highlight treatment of Ineffective Esophageal Motility, Distal Esophageal Spasm, Achalasia, Esophagogastric Junction Outflow Obstruction, Absent Contractility, and Hypercontractile Esophagus.
This session provides a deeper understanding of how and when to use our current state of the art tools for physiology testing. Audience members will appreciate the nuances of esophageal motility reading, when to order which pH test for reflux symptoms. This session will also focus on the currently identified esophageal motility disorders as per the Chicago Classification version 4.0. This will highlight potential therapeutic options for these disorders. Attendees will hear about non-achalasia motility disorders and focus on current studies that highlight treatment of Ineffective Esophageal Motility, Distal Esophageal Spasm, Achalasia, Esophagogastric Junction Outflow Obstruction, Absent Contractility, and Hypercontractile Esophagus.
Presenter
University of Pennsylvania
Tracks
Related Products
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
INTRODUCTION
SOCIETY: AGA
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PANEL DISCUSSION
GERD refractory to standard therapy is a common problem in clinical practice. The causes are multiple and there is a need for a rational evidence based approach to this problem…
